Published by Sally Church on Pharma Strategy Blog
Sanofi-aventis have just announced :
“A randomized Phase III trial evaluating BSI-201 (iniparib*) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival.”
Iniparib was thought to offer the best chance of success with PARP inhibitors because the others have so far been shown to be
- more potent
- more challenging to combine given the toxicities involved.
Clearly it is a fine line between potency and toxicities with this particular class.
Click here to read the full post on Pharma Strategy Blog